AIM Shareholders Elect All Four Company Director Nominees at 2023 Annual Meeting

Rhea-AI Summary

AIM ImmunoTech Inc. (AIM) announces the election of all four directors at the 2023 Annual Meeting of Stockholders. The company expresses gratitude to shareholders and emphasizes commitment to delivering life-saving treatments and creating shareholder value.

OCALA, Fla.--(BUSINESS WIRE)-- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that shareholders have elected all four of the Company’s directors, Stewart L. Appelrouth, Nancy K. Bryan, Thomas K. Equels and William M. Mitchell, at the Company’s 2023 Annual Meeting of Stockholders (the “2023 Annual Meeting”) held today.

AIM issued the following statement:

“We would like to thank our shareholders for their support and engagement throughout this process. Our Board and management team are fully committed to our mission of delivering life-saving treatments for unmet patient needs and creating value for shareholders. We look forward to achieving additional near-term clinical milestones as we build on our recent significant momentum and will keep investors updated on an ongoing basis.”

The results announced today are considered preliminary until final results are tabulated and certified by the independent Inspector of Elections. The Company will file the final voting results on a Form 8-K with the Securities and Exchange Commission.

About AIM ImmunoTech Inc.

AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company’s lead product is a first-in-class investigational drug called Ampligen® (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system.

For more information, please visit aimimmuno.com and connect with the Company on Twitter, LinkedIn, and Facebook.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the “PSLRA”). Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “continue,” “believe,” “potential,” “upcoming” and other variations thereon and similar expressions (as well as other words or expressions referencing future events or circumstances) are intended to identify forward-looking statements. Many of these forward-looking statements involve a number of risks and uncertainties. The Company urges investors to consider specifically the various risk factors identified in its most recent Form 10-K, and any risk factors or cautionary statements included in any subsequent Form 10-Q or Form 8-K, filed with the U.S. Securities and Exchange Commission (the “SEC”). You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Among other things, for those statements, the Company claims the protection of safe harbor for forward-looking statements contained in the PSLRA. The Company does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240105031286/en/

Investor Contact:

JTC Team, LLC

Jenene Thomas

833-475-8247

AIM@jtcir.com



Media Contact:

Longacre Square Partners

Joe Germani / Miller Winston

AIM@longacresquare.com

Source: AIM ImmunoTech Inc.

Who were elected as directors at AIM ImmunoTech Inc.'s 2023 Annual Meeting of Stockholders?

Stewart L. Appelrouth, Nancy K. Bryan, Thomas K. Equels, and William M. Mitchell were elected as directors at AIM ImmunoTech Inc.'s 2023 Annual Meeting of Stockholders.

What is the ticker symbol for AIM ImmunoTech Inc.?

The ticker symbol for AIM ImmunoTech Inc. is AIM.

When will the final voting results be filed with the Securities and Exchange Commission?

The final voting results will be filed on a Form 8-K with the Securities and Exchange Commission.

What is the mission of AIM ImmunoTech Inc.?

AIM ImmunoTech Inc.'s mission is to deliver life-saving treatments for unmet patient needs and create value for shareholders.

What are the next steps for AIM ImmunoTech Inc. after the 2023 Annual Meeting of Stockholders?

AIM ImmunoTech Inc. looks forward to achieving additional near-term clinical milestones and will keep investors updated on an ongoing basis.